Mesa Laboratories, Inc. (MLAB) Holdings Raised by DF Dent & Co. Inc.

DF Dent & Co. Inc. raised its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 3.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,932 shares of the medical instruments supplier’s stock after acquiring an additional 396 shares during the quarter. DF Dent & Co. Inc. owned approximately 0.29% of Mesa Laboratories worth $1,359,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Candriam Luxembourg S.C.A. raised its holdings in Mesa Laboratories by 20.0% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 7,200 shares of the medical instruments supplier’s stock valued at $895,000 after acquiring an additional 1,200 shares during the period. State Street Corp raised its holdings in Mesa Laboratories by 7.5% during the second quarter. State Street Corp now owns 56,252 shares of the medical instruments supplier’s stock valued at $8,063,000 after acquiring an additional 3,943 shares during the period. Wells Fargo & Company MN raised its holdings in Mesa Laboratories by 31.4% during the third quarter. Wells Fargo & Company MN now owns 4,371 shares of the medical instruments supplier’s stock valued at $653,000 after acquiring an additional 1,045 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Mesa Laboratories by 149.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 11,976 shares of the medical instruments supplier’s stock valued at $1,789,000 after acquiring an additional 7,176 shares during the period. Finally, Thomson Horstmann & Bryant Inc. raised its holdings in Mesa Laboratories by 14.5% during the fourth quarter. Thomson Horstmann & Bryant Inc. now owns 88,379 shares of the medical instruments supplier’s stock valued at $10,985,000 after acquiring an additional 11,164 shares during the period. 73.24% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

MLAB has been the topic of several research reports. BidaskClub raised Mesa Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, March 15th. TheStreet cut Mesa Laboratories from a “b-” rating to a “c” rating in a report on Wednesday, February 7th. Finally, Zacks Investment Research raised Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 9th.

In related news, Director Robert V. Dwyer sold 5,000 shares of Mesa Laboratories stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $144.01, for a total value of $720,050.00. Following the completion of the transaction, the director now owns 68,521 shares in the company, valued at $9,867,709.21. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Bradley Schmieder sold 3,000 shares of Mesa Laboratories stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the director now owns 77,869 shares of the company’s stock, valued at approximately $10,299,732.63. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,000 shares of company stock valued at $1,668,860. 15.70% of the stock is currently owned by company insiders.

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) opened at $142.01 on Tuesday. Mesa Laboratories, Inc. has a twelve month low of $117.71 and a twelve month high of $169.80. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.37 and a quick ratio of 1.64. The stock has a market capitalization of $565.58, a PE ratio of 63.62 and a beta of 0.59.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Monday, February 5th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by ($0.77). Mesa Laboratories had a positive return on equity of 9.20% and a negative net margin of 3.82%. The firm had revenue of $23.67 million during the quarter, compared to the consensus estimate of $23.10 million. research analysts anticipate that Mesa Laboratories, Inc. will post -1.18 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, March 15th. Stockholders of record on Wednesday, February 28th were issued a $0.16 dividend. The ex-dividend date was Tuesday, February 27th. This represents a $0.64 annualized dividend and a dividend yield of 0.45%. Mesa Laboratories’s dividend payout ratio (DPR) is -64.00%.

COPYRIGHT VIOLATION WARNING: “Mesa Laboratories, Inc. (MLAB) Holdings Raised by DF Dent & Co. Inc.” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2018/03/20/mesa-laboratories-inc-mlab-holdings-raised-by-df-dent-co-inc.html.

Mesa Laboratories Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply